200 related articles for article (PubMed ID: 35408914)
41. Exploring the efficacy and safety of Ambroxol in Gaucher disease: an overview of clinical studies.
Mohamed FE; Al-Jasmi F
Front Pharmacol; 2024; 15():1335058. PubMed ID: 38414738
[TBL] [Abstract][Full Text] [Related]
42. [Pharmacological chaperone therapy for the treatment of inborn errors of metabolism].
Lipiński P; Jezela-Stanek A; Tylki-Szymańska A
Postepy Biochem; 2022 Sep; 68(3):255-263. PubMed ID: 36317990
[TBL] [Abstract][Full Text] [Related]
43. Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice.
Migdalska-Richards A; Daly L; Bezard E; Schapira AH
Ann Neurol; 2016 Nov; 80(5):766-775. PubMed ID: 27859541
[TBL] [Abstract][Full Text] [Related]
44. Selective chaperone effect of aminocyclitol derivatives on G202R and other mutant glucocerebrosidases causing Gaucher disease.
Serra-Vinardell J; Díaz L; Gutiérrez-de Terán H; Sánchez-Ollé G; Bujons J; Michelakakis H; Mavridou I; Aerts JM; Delgado A; Grinberg D; Vilageliu L; Casas J
Int J Biochem Cell Biol; 2014 Sep; 54():245-54. PubMed ID: 25084554
[TBL] [Abstract][Full Text] [Related]
45. The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms.
Steet RA; Chung S; Wustman B; Powe A; Do H; Kornfeld SA
Proc Natl Acad Sci U S A; 2006 Sep; 103(37):13813-8. PubMed ID: 16945909
[TBL] [Abstract][Full Text] [Related]
46. Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations.
Alfonso P; Pampín S; Estrada J; Rodríguez-Rey JC; Giraldo P; Sancho J; Pocoví M
Blood Cells Mol Dis; 2005; 35(2):268-76. PubMed ID: 16039881
[TBL] [Abstract][Full Text] [Related]
47. Generation of wild-type rat Glucocerebrosidase homology modeling: Identification of putative interactions site and mechanism for chaperone using combined in-silico and in-vitro studies.
Tripathi P; Ganeshpurkar A; Singh SK; Krishnamurthy S
Bioorg Chem; 2022 Sep; 126():105871. PubMed ID: 35605554
[TBL] [Abstract][Full Text] [Related]
48. Isofagomine induced stabilization of glucocerebrosidase.
Kornhaber GJ; Tropak MB; Maegawa GH; Tuske SJ; Coales SJ; Mahuran DJ; Hamuro Y
Chembiochem; 2008 Nov; 9(16):2643-9. PubMed ID: 18932186
[TBL] [Abstract][Full Text] [Related]
49. Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant.
Bendikov-Bar I; Ron I; Filocamo M; Horowitz M
Blood Cells Mol Dis; 2011 Jan; 46(1):4-10. PubMed ID: 21106416
[TBL] [Abstract][Full Text] [Related]
50. Diltiazem, a L-type Ca(2+) channel blocker, also acts as a pharmacological chaperone in Gaucher patient cells.
Rigat B; Mahuran D
Mol Genet Metab; 2009 Apr; 96(4):225-32. PubMed ID: 19167257
[TBL] [Abstract][Full Text] [Related]
51. Functional screening of pharmacological chaperones via restoration of enzyme activity upon denaturation.
Shanmuganathan M; Britz-McKibbin P
Biochemistry; 2012 Oct; 51(39):7651-3. PubMed ID: 22970758
[TBL] [Abstract][Full Text] [Related]
52. The effect of N-octyl-β-valienamine on β-glucosidase activity in tissues of normal mice.
Luan Z; Ninomiya H; Ohno K; Ogawa S; Kubo T; Iida M; Suzuki Y
Brain Dev; 2010 Nov; 32(10):805-9. PubMed ID: 20074885
[TBL] [Abstract][Full Text] [Related]
53. Early initiation of ambroxol treatment diminishes neurological manifestations of type 3 Gaucher disease: A long-term outcome of two siblings.
Ramadža DP; Zekušić M; Žigman T; Škaričić A; Bogdanić A; Mustać G; Bošnjak-Nađ K; Ozretić D; Ohno K; Fumić K; Barić I
Eur J Paediatr Neurol; 2021 May; 32():66-72. PubMed ID: 33836415
[TBL] [Abstract][Full Text] [Related]
54. Isofagomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention.
Yu Z; Sawkar AR; Whalen LJ; Wong CH; Kelly JW
J Med Chem; 2007 Jan; 50(1):94-100. PubMed ID: 17201413
[TBL] [Abstract][Full Text] [Related]
55. Design of a New α-1-
Nakagome I; Kato A; Yamaotsu N; Yoshida T; Ozawa SI; Adachi I; Hirono S
Molecules; 2018 Oct; 23(10):. PubMed ID: 30340368
[TBL] [Abstract][Full Text] [Related]
56. Identification of pharmacological chaperones for Gaucher disease and characterization of their effects on beta-glucocerebrosidase by hydrogen/deuterium exchange mass spectrometry.
Tropak MB; Kornhaber GJ; Rigat BA; Maegawa GH; Buttner JD; Blanchard JE; Murphy C; Tuske SJ; Coales SJ; Hamuro Y; Brown ED; Mahuran DJ
Chembiochem; 2008 Nov; 9(16):2650-62. PubMed ID: 18972510
[TBL] [Abstract][Full Text] [Related]
57. Assessment of cellular cobalamin metabolism in Gaucher disease.
Basgalupp SP; Siebert M; Ferreira C; Behringer S; Spiekerkoetter U; Hannibal L; Schwartz IVD
BMC Med Genet; 2020 Jan; 21(1):12. PubMed ID: 31931749
[TBL] [Abstract][Full Text] [Related]
58. Conformationally-locked C-glycosides: tuning aglycone interactions for optimal chaperone behaviour in Gaucher fibroblasts.
Navo CD; Corzana F; Sánchez-Fernández EM; Busto JH; Avenoza A; Zurbano MM; Nanba E; Higaki K; Ortiz Mellet C; García Fernández JM; Peregrina JM
Org Biomol Chem; 2016 Jan; 14(4):1473-84. PubMed ID: 26690983
[TBL] [Abstract][Full Text] [Related]
59. Conformationally-locked N-glycosides with selective β-glucosidase inhibitory activity: identification of a new non-iminosugar-type pharmacological chaperone for Gaucher disease.
Castilla J; Rísquez R; Cruz D; Higaki K; Nanba E; Ohno K; Suzuki Y; Díaz Y; Ortiz Mellet C; García Fernández JM; Castillón S
J Med Chem; 2012 Aug; 55(15):6857-65. PubMed ID: 22762530
[TBL] [Abstract][Full Text] [Related]
60. trans, trans-2-C-Aryl-3,4-dihydroxypyrrolidines as potent and selective β-glucosidase inhibitors: Pharmacological chaperones for Gaucher disease.
Wang JZ; Shimadate Y; Kise M; Kato A; Jia YM; Li YX; Fleet GWJ; Yu CY
Eur J Med Chem; 2022 Aug; 238():114499. PubMed ID: 35675756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
